A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity.

Dicks MD, Spencer AJ, Edwards NJ, Wadell G, Bojang K, Gilbert SC, Hill AV, Cottingham MG. · 2012

Read A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity. by Dicks MD, Spencer AJ, Edwards NJ, Wadell G, Bojang K, Gilbert SC, Hill AV, Cottingham MG. (2012) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc3396660.txt.

Introduction

Dicks and colleagues derived a new vaccine delivery virus in 2012 from a chimpanzee adenovirus called Y25. Adenoviruses make promising vaccine shuttles, but prior exposure to common human types can blunt them. Rare animal types dodge that problem. The team also fixed how virus doses are measured, since sloppy counts can distort comparisons.

Built in an artificial chromosome for easy editing, the new vector raised cell-level immune responses in mice on par with a leading chimp virus already in human trials. Blood surveys in Britain and Gambia found especially few people carrying antibodies against it. Those two results support taking the Y25 vector toward clinical use.

Catalog record

CREATORDicks MD, Spencer AJ, Edwards NJ, Wadell G, Bojang K, Gilbert SC, Hill AV, Cottingham MG.
YEAR2012
COLLECTIONPAPERS
FORMATTXT
FILE SIZE58 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC3396660

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

A Novel Chimpanzee Adenovirus Vector with Low Human Seroprevalence: Improved Systems for Vector Derivation and Comparative Immunogenicity By Matthew D. J. Dicks, Alexandra J. Spencer, Nick J. Edwards, Göran Wadell, Kalifa Bojang, Sarah C. Gilbert, Adrian V. S. Hill, Matthew G. Cottingham, Eric J. Kremer Published in: PLoS ONE DOI: 10.1371/journal.pone.0040385 ABSTRACT Recombinant adenoviruses are among the most promising tools for vaccine antigen delivery. Recently, the development of new vectors has focused on serotypes to which the human population is less exposed in order to circumvent pre-existing anti vector immunity. This study describes the derivation of a new vaccine vector based on a chimpanzee adenovirus, Y25, together with a comparative assessment of its potential to elicit transgene product specific immune responses in mice. The vector was constructed in a bacterial artificial chromosome to facilitate genetic manipulation of genomic clones. In order to conduct a fair head-to-head immunological comparison of multiple adenoviral vectors, we optimised a method for accurate determination of infectious titre, since this parameter exhibits profound natural variability and can confound immunogenicity studies when doses are based on viral particle estimation. Cellular immunogenicity of recombinant E1 E3-deleted vector ChAdY25 was comparable to that of other species E derived chimpanzee adenovirus vectors including ChAd63, the first simian adenovirus vector to enter clinical trials in humans. Furthermore, the prevalence of virus neutralizing antibodies (titre >1∶200) against ChAdY25 in serum samples collected from two human populations in the UK and Gambia was particularly low compared to published data for other chimpanzee adenoviruses. These findings support the continued development of new chimpanzee adenovirus vectors, including ChAdY25, for clinical use. INTRODUCTION Recombinant adenoviruses were originally developed for gene therapy [1], but the strong and sustained transgene-specific immune responses elicited by these delivery agents, together with their broad tissue tropism, has prompted their use as vaccine vectors [2]. Deletion of a single transcriptional unit, E1, renders the virus replication incompetent, reducing the potential for side effects in clinical applications. Deletion of a second unit, E3, increases the insert capacity to 8 kb, allowing flexibility in antigen design, and does not affect growth in an E1-complementing cell line. The first generation of vaccine vectors based on human adenovirus type 5 (HAdV-5), the most widely studied adenoviral serotype, showed poor efficacy in HIV-1 clinical trials despite encouraging pre-clinical data [3], [4]. A large proportion of human adults possess significant titres of neutralising antibodies to common human serotypes such as HAdV-2 and HAdV-5. Neutralising antibodies have the potential to reduce the potency of viral vector vaccines by inhibiting vector mediated delivery of the encoded transgene. Pre-existing anti vector immunity has since been addressed through the development of new vectors based on serotypes to which the human population is less exposed, including those of chimpanzee origin [5], [6], [7]. Chimpanzee adenoviral vectors have been shown to be highly immunogenic in animal models [8], [9] and recently in clinical malaria vaccine trials [10], [11]. Adenovirus vectored vaccines have been widely used in early stage clinical trials targeting a range of diseases including malaria, HIV, influenza, hepatitis C, and cancer [12]. However, despite the large number of clinical trials, to date only a handful of serotypes (HAdV-5, HAdV-6, HAdV-35 and two chimpanzee adenovirus serotypes ChAd63 and ChAd3) have been assessed as vaccine vectors in humans. There is a need for development of new vectors for clinical application, both to assess the utility of different serotypes and to enable deployment of multiple vaccines within a single population, since anti-vector immunity after immunisation may limit the efficacy of a second immunisation with the same vector [13]. New vectors will need to be based on viruses that have low seroprevalence in humans, and are able to elicit robust transgene product specific immune responses. Here we describe the development of a new adenoviral vector based on a chimpanzee adenoviral isolate Y25 [14], the genomic sequence of which we report here. We used a bacterial artificial chromosome (BAC) system to generate a molecular clone of the virus, to which precise genetic modifications were made through BAC recombineering [15]. The same method was also applied to re-derivation of a BAC clone of SAdV-25 (also known as AdC68 and Pan 9 [5]). This approach offers superior flexibility and speed of vector modification over previously reported methods, as well as improved genetic stability [16]. We demonstrate experimentally that the infectivity of adenoviral vector preparations is the principal determinant of immunogenicity (rather than viral particle count) [7] and use a single cell infectivity assay to assess infectious titer more accurately and conveniently than the traditional plaque assay or endpoint dilution methods. Using this improved strategy, we show, in both single immunisation and prime boost regimens, that cellular immunogenicity of new vector ChAdY25 in mice is equivalent to that of existing chimpanzee adenoviral vectors. Our comparison includes ChAd63, previously shown to be highly immunogenic in man [10], [11]. The seroprevalence of vector neutralising antibodies against Y25 was found to be similar to or lower than previously reported for other chimpanzee adenoviruses in the British and Gambian human populations tested. We therefore propose that ChAdY25 also has the potential to be an efficacious vaccine vector in human clinical trials. MATERIALS AND METHODS Ethics Statement All mouse procedures were performed in accordance with the terms of the UK Animals (Scientific Procedures) Act Project Licence (PPL 30/2414) and were approved by the University of Oxford Animal Care and Ethical Review Committee. For clinical samples, all human volunteers gave written informed consent prior to participation and the studies were conducted according to the principles of the Declaration of Helsinki and in accordance with Good Clinical Practice (GCP). UK samples were obtained from trials MAL34 (NCT00890760) and VAC33 (NCT00890019). For these trials, approvals were granted by the Oxfordshire Research Ethics Committee (OXREC), the Medicines and Healthcare products Regulatory Agency (MHRA) and the Gene Therapy Advisory Committee (GTAC). Gambian samples were obtained from trial VAC41 (NCT01373879) with approval from Oxford Tropical Research Ethics Committee and the State Services Commission (SSC). Viruses and Cells The wild type chimpanzee adenovirus isolate Y25 was originally obtained from William Hillis, John Hopkins University of Medicine. The virus was passaged in HEK293A cells (Invitrogen, Cat. R705-07) and purified by CsCl gradient ultracentrifugation as previously described [17]. Viral DNA was phenol extracted for genomic sequencing and cloning. An AdC68 vector (also known as Pan9 [18]) was independently rederived from genomic DNA isolated from wild-type SAdV-25 virus obtained from ATCC using a similar method to that described here for Y25 (Y. Roshorm et al., manuscript in preparation). The ChAd63 vector was provided by Okairòs AG, Italy. Genome Sequencing and Phylogenetic Analysis Sequencing of the Y25 viral genome was performed by Eurofins MWG Operon AG using GS SLX Titanium Series technology. Previously reported sequences were obtained from Genbank, accession numbers as follows: ChAd3 CS479276; ChAd63 CS479277; HAdV-5 AC_000008; SAdV-22 AY530876; SAdV-25 AF394196, HAdV-1 AF534906; HAdV-2 J01917; HAdV-4 AY458656; HAdV-6 FJ349096; HAdV-12 X73487; HAdV-16 AY601636;; HAdV-30 DQ149628; HAdV-10 AB369368, AB330091; HAdV-17 HQ910407; HAdV-9 AJ854486; HAdV-37 AB448776; HAdV-8 AB448767; HAdV-7 AB243119, AB243118; HAdV-11 AC_000015; HAdV-21 AY601633; HAdV-34 AY737797; HAdV-35 AC_000019; HAdV-40 NC_001454; HAdV-41 DQ315364; SAdV-21 AC_000010; SAdV-23 AY530877; SAdV-24 AY530878; HAdV-3 DQ086466; HAdV-18 GU191019; HAdV-31 AM749299; HAdV-19 AB448774; SAdV-25.2 FJ025918; SAdV-30 FJ025920; SAdV-26 FJ025923; SAdV-38 FJ025922; SAdV-39

Read the complete text